{"id": "article-144392_0", "title": "Mild Cognitive Impairment -- Introduction", "content": "Memory loss is a common complaint among older adults, and cognitive decline can present in various ways. It\u00a0is a part of the normal aging process, subjective cognitive impairment (symptomatic complaints with normal neurocognitive test results), mild cognitive impairment, or dementia. [1] Although mild cognitive impairment (MCI) has been used in the literature since the 1960s, it was first fully characterized in 1997 by Petersen and colleagues at the Mayo Clinic. As part of their community aging study, they observed individuals with memory concerns beyond what was expected for their age. They demonstrated memory impairment on objective testing yet did not fulfill the criteria for dementia. [2] MCI was\u00a0deemed to represent a borderline between normal aging and very early dementia. The earlier criteria for MCI diagnosis were found inadequate when it was realized that not all patients with MCI progressed to dementia and that memory impairment was not the only cognitive domain affected. [2] Thus, a broader definition of MCI was needed. In 2003, the first Key Symposium on MCI was held, leading to the publication of revised core clinical criteria. [3] These criteria included cognitive complaints from the patient or family members, deficits in any cognitive domain and not only memory, preserved overall general function but\u00a0increasing\u00a0difficulties in activities of daily life, and no dementia. [4] The concept of MCI traveled outside the realm of research to provide clinicians with a useful diagnosis, often for close monitoring. Further clinical research resulted in the development of novel clinical criteria for providers.", "contents": "Mild Cognitive Impairment -- Introduction. Memory loss is a common complaint among older adults, and cognitive decline can present in various ways. It\u00a0is a part of the normal aging process, subjective cognitive impairment (symptomatic complaints with normal neurocognitive test results), mild cognitive impairment, or dementia. [1] Although mild cognitive impairment (MCI) has been used in the literature since the 1960s, it was first fully characterized in 1997 by Petersen and colleagues at the Mayo Clinic. As part of their community aging study, they observed individuals with memory concerns beyond what was expected for their age. They demonstrated memory impairment on objective testing yet did not fulfill the criteria for dementia. [2] MCI was\u00a0deemed to represent a borderline between normal aging and very early dementia. The earlier criteria for MCI diagnosis were found inadequate when it was realized that not all patients with MCI progressed to dementia and that memory impairment was not the only cognitive domain affected. [2] Thus, a broader definition of MCI was needed. In 2003, the first Key Symposium on MCI was held, leading to the publication of revised core clinical criteria. [3] These criteria included cognitive complaints from the patient or family members, deficits in any cognitive domain and not only memory, preserved overall general function but\u00a0increasing\u00a0difficulties in activities of daily life, and no dementia. [4] The concept of MCI traveled outside the realm of research to provide clinicians with a useful diagnosis, often for close monitoring. Further clinical research resulted in the development of novel clinical criteria for providers."}
{"id": "article-144392_1", "title": "Mild Cognitive Impairment -- Introduction", "content": "The American Psychiatry Association's Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) in 2013 classified MCI as one of the neurocognitive disorders (NCD). It is characterized by a decline in one or more cognitive domains, which is both subjectively and objectively observable. However, this decline does not interfere with the individual's ability to perform daily activities independently. Moreover, the deficits cannot be attributed to delirium or other psychiatric conditions. [4] DSM-V does not propose specific neuropsychology test scores for diagnosing mild NCD. However, it is implied that such scores would help make this diagnosis. After diagnosing the syndrome as mild NCD, the next step\u00a0is determining the etiology. [3] The 11th Revision of the International Classification of Diseases (ICD 11) by the World Health Organization (WHO) in 2018 adopted the definition of mild neurocognitive disorder in alignment with the DSM-V diagnostic criteria. [4]", "contents": "Mild Cognitive Impairment -- Introduction. The American Psychiatry Association's Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) in 2013 classified MCI as one of the neurocognitive disorders (NCD). It is characterized by a decline in one or more cognitive domains, which is both subjectively and objectively observable. However, this decline does not interfere with the individual's ability to perform daily activities independently. Moreover, the deficits cannot be attributed to delirium or other psychiatric conditions. [4] DSM-V does not propose specific neuropsychology test scores for diagnosing mild NCD. However, it is implied that such scores would help make this diagnosis. After diagnosing the syndrome as mild NCD, the next step\u00a0is determining the etiology. [3] The 11th Revision of the International Classification of Diseases (ICD 11) by the World Health Organization (WHO) in 2018 adopted the definition of mild neurocognitive disorder in alignment with the DSM-V diagnostic criteria. [4]"}
{"id": "article-144392_2", "title": "Mild Cognitive Impairment -- Introduction", "content": "The National Institute on Aging and the Alzheimer's Association (NIA-AA) convened a work group to discuss the MCI criteria. The group proposed metrics for the distinct definition of MCI due to Alzheimer Disease. The initial criteria were published in 2011 and revised in 2018. The initial criteria closely resemble the core clinical criteria proposed by the 2003 Symposium. The 2018 revision noted that neurobehavioral disturbance may be an important feature of the clinical presentation and that cognitive deficits may result in a mild but noticeable impact on the complex activities of daily living. [4] The NIA-AA also suggested research criteria for MCI due to AD in 2011 to help determine the etiology of MCI established by the core clinical criteria. These included the use of biomarkers to differentiate MCI due to AD from MCI due to other reasons. The biomarkers are not used to define MCI but can be helpful in research settings. The two main helpful biomarkers are amyloid-beta (A\u03b2) deposition and neuronal injury. [5] [3]", "contents": "Mild Cognitive Impairment -- Introduction. The National Institute on Aging and the Alzheimer's Association (NIA-AA) convened a work group to discuss the MCI criteria. The group proposed metrics for the distinct definition of MCI due to Alzheimer Disease. The initial criteria were published in 2011 and revised in 2018. The initial criteria closely resemble the core clinical criteria proposed by the 2003 Symposium. The 2018 revision noted that neurobehavioral disturbance may be an important feature of the clinical presentation and that cognitive deficits may result in a mild but noticeable impact on the complex activities of daily living. [4] The NIA-AA also suggested research criteria for MCI due to AD in 2011 to help determine the etiology of MCI established by the core clinical criteria. These included the use of biomarkers to differentiate MCI due to AD from MCI due to other reasons. The biomarkers are not used to define MCI but can be helpful in research settings. The two main helpful biomarkers are amyloid-beta (A\u03b2) deposition and neuronal injury. [5] [3]"}
{"id": "article-144392_3", "title": "Mild Cognitive Impairment -- Introduction", "content": "MCI can also be classified based on the type of cognitive domain that is affected. MCI can potentially affect one or more of the following 6 cognitive domains: learning and memory, language, complex attention, executive function, social cognition, and visuospatial function. [6] MCI can be classified as \"amnestic\" or \"non-amnestic\" with deficits in single or multiple cognitive domains. Amnestic MCI presents with predominant memory loss and the risk for progression to Alzheimer's Disease. In non-amnestic MCI, memory is relatively intact, and it is less common than the amnestic type and may progress to non-Alzheimer disease dementia. [6] [4] MCI can be further categorized into\u00a04 subtypes: [2] [1]", "contents": "Mild Cognitive Impairment -- Introduction. MCI can also be classified based on the type of cognitive domain that is affected. MCI can potentially affect one or more of the following 6 cognitive domains: learning and memory, language, complex attention, executive function, social cognition, and visuospatial function. [6] MCI can be classified as \"amnestic\" or \"non-amnestic\" with deficits in single or multiple cognitive domains. Amnestic MCI presents with predominant memory loss and the risk for progression to Alzheimer's Disease. In non-amnestic MCI, memory is relatively intact, and it is less common than the amnestic type and may progress to non-Alzheimer disease dementia. [6] [4] MCI can be further categorized into\u00a04 subtypes: [2] [1]"}
{"id": "article-144392_4", "title": "Mild Cognitive Impairment -- Introduction", "content": "In 2009, a comprehensive Neuropsychology classification system was introduced as the dichotomous classification was considered inadequate to represent the heterogeneous nature of MCI. [7] These MCI classes are: Amnestic - impaired recall and recognition Mixed - impairments in various domains such as language, executive function, recall and recognition, and visuospatial functioning. Dysexecutive - impairments in attention, executive, and visuospatial functions, but the memory remains intact. Visuospatial - impairment in only a single measure of visual construction.", "contents": "Mild Cognitive Impairment -- Introduction. In 2009, a comprehensive Neuropsychology classification system was introduced as the dichotomous classification was considered inadequate to represent the heterogeneous nature of MCI. [7] These MCI classes are: Amnestic - impaired recall and recognition Mixed - impairments in various domains such as language, executive function, recall and recognition, and visuospatial functioning. Dysexecutive - impairments in attention, executive, and visuospatial functions, but the memory remains intact. Visuospatial - impairment in only a single measure of visual construction."}
{"id": "article-144392_5", "title": "Mild Cognitive Impairment -- Introduction", "content": "The phenotypic classification of MCI with clinical information and laboratory tests can guide the clinician in determining the probable cause of MCI and predicting its course. Patients with dysexecutive MCI (dMCI) are less likely to have Alzheimer - type dementia and more likely to have a stroke. [7]", "contents": "Mild Cognitive Impairment -- Introduction. The phenotypic classification of MCI with clinical information and laboratory tests can guide the clinician in determining the probable cause of MCI and predicting its course. Patients with dysexecutive MCI (dMCI) are less likely to have Alzheimer - type dementia and more likely to have a stroke. [7]"}
{"id": "article-144392_6", "title": "Mild Cognitive Impairment -- Etiology", "content": "There are various risk factors for MCI.", "contents": "Mild Cognitive Impairment -- Etiology. There are various risk factors for MCI."}
{"id": "article-144392_7", "title": "Mild Cognitive Impairment -- Etiology -- Non-Modifiable Risk Factors", "content": "Advancing age is the strongest risk factor for MCI. Other risk factors include male sex, family history of cognitive impairment, and the presence of the apolipoprotein E (APOE) allele. [6] The APOE\u00a0\u03b54 allele is the most frequent genetic risk factor associated with the progression of MCI to Alzheimer dementia. Some studies have reported an increased risk of progression to Alzheimer dementia in both carriers and homozygotes for APOE\u00a0\u03b54 allele, while other studies have not found any association. Hence, the clinical utility of using the APOE genotype is limited. [8]", "contents": "Mild Cognitive Impairment -- Etiology -- Non-Modifiable Risk Factors. Advancing age is the strongest risk factor for MCI. Other risk factors include male sex, family history of cognitive impairment, and the presence of the apolipoprotein E (APOE) allele. [6] The APOE\u00a0\u03b54 allele is the most frequent genetic risk factor associated with the progression of MCI to Alzheimer dementia. Some studies have reported an increased risk of progression to Alzheimer dementia in both carriers and homozygotes for APOE\u00a0\u03b54 allele, while other studies have not found any association. Hence, the clinical utility of using the APOE genotype is limited. [8]"}
{"id": "article-144392_8", "title": "Mild Cognitive Impairment -- Etiology -- Chronic Medical Conditions and Multimorbidity", "content": "Vascular risk factors such as hypertension, hyperlipidemia, coronary artery disease, and stroke are associated with MCI. A study focused on multimorbidity and MCI showed that patients with\u00a04 or more comorbid conditions, especially\u00a02 of the following: hypertension, coronary artery disease, hyperlipidemia, and osteoarthritis, have an increased risk of MCI. [6] [8] Other chronic diseases, such as chronic obstructive pulmonary disease and diabetes mellitus, are also risk factors for MCI. [6]", "contents": "Mild Cognitive Impairment -- Etiology -- Chronic Medical Conditions and Multimorbidity. Vascular risk factors such as hypertension, hyperlipidemia, coronary artery disease, and stroke are associated with MCI. A study focused on multimorbidity and MCI showed that patients with\u00a04 or more comorbid conditions, especially\u00a02 of the following: hypertension, coronary artery disease, hyperlipidemia, and osteoarthritis, have an increased risk of MCI. [6] [8] Other chronic diseases, such as chronic obstructive pulmonary disease and diabetes mellitus, are also risk factors for MCI. [6]"}
{"id": "article-144392_9", "title": "Mild Cognitive Impairment -- Etiology -- Polypharmacy", "content": "Numerous classes and combinations of medications can have adverse impacts on memory. These include both prescription and over-the-counter medications. Some of the common classes are opiates, anxiolytics such as benzodiazepines, non-benzodiazepine sedatives/hypnotics such as zolpidem, muscle relaxants, antiepileptic, and anticholinergic medications. [9] Anticholinergic medications include antihistamines, antidepressants, urinary incontinence medications, and antipsychotics. [6] [10] Antihypertensive medications can affect cognition by causing orthostatic hypotension. Hypoglycemia due to side effects from antidiabetic agents or hyperglycemia from inadequate treatment of diabetes can cause cognitive deficits. [6] Drug-to-drug interactions between medication classes can also cause cognitive loss. Medication side effects are reversible and can be improved if recognized promptly.", "contents": "Mild Cognitive Impairment -- Etiology -- Polypharmacy. Numerous classes and combinations of medications can have adverse impacts on memory. These include both prescription and over-the-counter medications. Some of the common classes are opiates, anxiolytics such as benzodiazepines, non-benzodiazepine sedatives/hypnotics such as zolpidem, muscle relaxants, antiepileptic, and anticholinergic medications. [9] Anticholinergic medications include antihistamines, antidepressants, urinary incontinence medications, and antipsychotics. [6] [10] Antihypertensive medications can affect cognition by causing orthostatic hypotension. Hypoglycemia due to side effects from antidiabetic agents or hyperglycemia from inadequate treatment of diabetes can cause cognitive deficits. [6] Drug-to-drug interactions between medication classes can also cause cognitive loss. Medication side effects are reversible and can be improved if recognized promptly."}
{"id": "article-144392_10", "title": "Mild Cognitive Impairment -- Etiology -- Psychiatric Risk Factors", "content": "Depression can cause both cognitive and physical impairment and\u00a0can present as MCI. The cognitive deficits can be reversed with adequate treatment of depression. Depression can also accelerate the progression of MCI to dementia. [6] Late-life anxiety has also been reported to be a risk factor for cognitive decline. [11]", "contents": "Mild Cognitive Impairment -- Etiology -- Psychiatric Risk Factors. Depression can cause both cognitive and physical impairment and\u00a0can present as MCI. The cognitive deficits can be reversed with adequate treatment of depression. Depression can also accelerate the progression of MCI to dementia. [6] Late-life anxiety has also been reported to be a risk factor for cognitive decline. [11]"}
{"id": "article-144392_11", "title": "Mild Cognitive Impairment -- Etiology -- Metabolic or Infectious Causes", "content": "Hypothyroidism, vitamin B12 deficiency, dehydration, hypo or hyperglycemia, and infections such as urinary tract infections can all cause cognitive impairment and are easily treated. [6]", "contents": "Mild Cognitive Impairment -- Etiology -- Metabolic or Infectious Causes. Hypothyroidism, vitamin B12 deficiency, dehydration, hypo or hyperglycemia, and infections such as urinary tract infections can all cause cognitive impairment and are easily treated. [6]"}
{"id": "article-144392_12", "title": "Mild Cognitive Impairment -- Etiology -- Sleep Disorders", "content": "Obstructive Sleep Apnea causes daytime fatigue and, if untreated, can cause cognitive dysfunction. The affected cognitive domains include executive function, attention, verbal or visual memory, visuospatial ability, and information processing. Continuous Positive Airway Pressure (CPAP) treatment may improve cognitive symptoms. [12]", "contents": "Mild Cognitive Impairment -- Etiology -- Sleep Disorders. Obstructive Sleep Apnea causes daytime fatigue and, if untreated, can cause cognitive dysfunction. The affected cognitive domains include executive function, attention, verbal or visual memory, visuospatial ability, and information processing. Continuous Positive Airway Pressure (CPAP) treatment may improve cognitive symptoms. [12]"}
{"id": "article-144392_13", "title": "Mild Cognitive Impairment -- Etiology -- Neurological Disorder", "content": "Normal Pressure Hydrocephalus is caused by cerebrospinal fluid (CSF) accumulation in the brain's ventricular system, causing ventricular enlargement. It presents as a triad of ataxic gait, urinary incontinence, and cognitive impairment. The cognitive changes are reversible if there is early diagnosis and treatment. [6]", "contents": "Mild Cognitive Impairment -- Etiology -- Neurological Disorder. Normal Pressure Hydrocephalus is caused by cerebrospinal fluid (CSF) accumulation in the brain's ventricular system, causing ventricular enlargement. It presents as a triad of ataxic gait, urinary incontinence, and cognitive impairment. The cognitive changes are reversible if there is early diagnosis and treatment. [6]"}
{"id": "article-144392_14", "title": "Mild Cognitive Impairment -- Etiology -- Neurological Disorder", "content": "MCI may also represent a prodromal stage of dementia. For some conditions, the disease manifests first with cognitive impairment in the later stage of the disease course. These conditions include Parkinson Disease (PD), traumatic brain injury (TBI), Huntington disease, Human Immunodeficiency Virus (HIV) infection, and cerebrovascular accident. The Movement Disorder Society (MDS) PD-MCI criteria require that impaired cognitive domains be specified to see whether different cognitive impairments progress at different rates. [13] There are other diseases where cognitive impairment is the first manifestation of the disease process, such as Alzheimer Disease, Lewy body disease, prion disease, frontotemporal dementia, and vascular dementia. MCI can be the prodromal stage; in these cases, it will progress to dementia. Amnestic MCI may progress to AD or vascular dementia, while non-amnestic MCI commonly develops into Lewy body disease or frontotemporal dementia. [6]", "contents": "Mild Cognitive Impairment -- Etiology -- Neurological Disorder. MCI may also represent a prodromal stage of dementia. For some conditions, the disease manifests first with cognitive impairment in the later stage of the disease course. These conditions include Parkinson Disease (PD), traumatic brain injury (TBI), Huntington disease, Human Immunodeficiency Virus (HIV) infection, and cerebrovascular accident. The Movement Disorder Society (MDS) PD-MCI criteria require that impaired cognitive domains be specified to see whether different cognitive impairments progress at different rates. [13] There are other diseases where cognitive impairment is the first manifestation of the disease process, such as Alzheimer Disease, Lewy body disease, prion disease, frontotemporal dementia, and vascular dementia. MCI can be the prodromal stage; in these cases, it will progress to dementia. Amnestic MCI may progress to AD or vascular dementia, while non-amnestic MCI commonly develops into Lewy body disease or frontotemporal dementia. [6]"}
{"id": "article-144392_15", "title": "Mild Cognitive Impairment -- Etiology -- Neurological Disorder", "content": "Some protective factors are associated with a reduced incidence of dementia or delayed dementia onset. These factors may also be protective for MCI. Higher education, bilingualism, and cognitively stimulating activities protect cognition. Lifestyle factors such as the Mediterranean diet, physical activity, smoking cessation, mild to moderate alcohol consumption, and participation in social activities are associated with reduced risk of cognitive impairment. [11] [3]", "contents": "Mild Cognitive Impairment -- Etiology -- Neurological Disorder. Some protective factors are associated with a reduced incidence of dementia or delayed dementia onset. These factors may also be protective for MCI. Higher education, bilingualism, and cognitively stimulating activities protect cognition. Lifestyle factors such as the Mediterranean diet, physical activity, smoking cessation, mild to moderate alcohol consumption, and participation in social activities are associated with reduced risk of cognitive impairment. [11] [3]"}
{"id": "article-144392_16", "title": "Mild Cognitive Impairment -- Epidemiology", "content": "MCI is a heterogeneous syndrome as there is a wide variation of cognitive and functional severity within the MCI definition. There are no standardized criteria for the diagnosis of MCI that have high clinical reliability and validity and provide consistent estimates across various studies. Hence, multiple studies have reported varying incidence and prevalence estimates. [14] The 2018 American Academy of Neurology (AAN) guideline update on MCI found that its prevalence is high among the older adult population and increases with age. The prevalence estimate was 6.7% in the 60-64 year age group and increased to 25.2% for ages 80-84. [15] Other studies have reported prevalence rates of up to 22% in community-dwelling older adults above 71 years of age and 40% among older adults in memory care practices. [8] Lower educational level was associated with a higher prevalence, while most studies found a similar prevalence in men and women. [15] Other studies have reported a higher prevalence in men. [9] The differences in the reported prevalence of MCI worldwide are due to the lack of standardized cut-off for neuropsychology test scores, use of population versus clinic-based cohorts, and algorithmic (non-informant-based) versus clinical approaches to assign the MCI diagnosis. [14] European studies reported a lower prevalence estimate than those reported by the US studies. Prevalence estimates were higher for those US studies conducted in urban settings and those that included ethnic groups other than Caucasians. [14] A recent study from China estimated that MCI prevalence was 15.5 % among Chinese adults. [16] There are fewer studies on the incidence rate of MCI. The reported incidence rate of MCI varies from 5.1 to 168 (1000 person-years), while that of A-MCI is estimated between 10 to 14 (1000 person-years). [14]", "contents": "Mild Cognitive Impairment -- Epidemiology. MCI is a heterogeneous syndrome as there is a wide variation of cognitive and functional severity within the MCI definition. There are no standardized criteria for the diagnosis of MCI that have high clinical reliability and validity and provide consistent estimates across various studies. Hence, multiple studies have reported varying incidence and prevalence estimates. [14] The 2018 American Academy of Neurology (AAN) guideline update on MCI found that its prevalence is high among the older adult population and increases with age. The prevalence estimate was 6.7% in the 60-64 year age group and increased to 25.2% for ages 80-84. [15] Other studies have reported prevalence rates of up to 22% in community-dwelling older adults above 71 years of age and 40% among older adults in memory care practices. [8] Lower educational level was associated with a higher prevalence, while most studies found a similar prevalence in men and women. [15] Other studies have reported a higher prevalence in men. [9] The differences in the reported prevalence of MCI worldwide are due to the lack of standardized cut-off for neuropsychology test scores, use of population versus clinic-based cohorts, and algorithmic (non-informant-based) versus clinical approaches to assign the MCI diagnosis. [14] European studies reported a lower prevalence estimate than those reported by the US studies. Prevalence estimates were higher for those US studies conducted in urban settings and those that included ethnic groups other than Caucasians. [14] A recent study from China estimated that MCI prevalence was 15.5 % among Chinese adults. [16] There are fewer studies on the incidence rate of MCI. The reported incidence rate of MCI varies from 5.1 to 168 (1000 person-years), while that of A-MCI is estimated between 10 to 14 (1000 person-years). [14]"}
{"id": "article-144392_17", "title": "Mild Cognitive Impairment -- Pathophysiology", "content": "MCI can have several outcomes, with the most important being the progression to dementia. Other cases\u00a0may revert to normal or remain stable in the MCI stage.", "contents": "Mild Cognitive Impairment -- Pathophysiology. MCI can have several outcomes, with the most important being the progression to dementia. Other cases\u00a0may revert to normal or remain stable in the MCI stage."}
{"id": "article-144392_18", "title": "Mild Cognitive Impairment -- Pathophysiology", "content": "A meta-analysis demonstrated that the cumulative incidence of dementia development was 14.9% for MCI patients older than 65 years who were followed for 2 years. The relative risk for all types of dementia was 3.3 at 2 to 5 years in a cohort of MCI patients and age-matched controls, while the relative risk for the development of Alzheimer Disease was 3.0. People with MCI are at a higher risk of progressing to dementia than age-matched controls. [15] The annual progression rate can be 12% in the general population and up to 20% in high-risk populations. [8] The risk factors for the development of MCI are not consistently associated with progression to dementia. Markers of cerebral dysfunction and those indicating the severity of underlying pathology are more consistently related to the risk of progressing to dementia. [14] More significant functional impairment, neuropsychiatric symptoms at the time of MCI diagnosis, lower neuropsychological test scores, and abnormalities on structural magnetic resonance imaging (hippocampal atrophy) are associated with a greater risk of conversion to dementia. [14] Some studies have noted that advanced age and amnestic MCI were associated with faster progression to dementia. [8] A stepwise multivariate regression analysis study reported that parietal glucose metabolic rate and total Tau proteins could predict progression from MCI to Alzheimer-type dementia. [17] The presence of APOE \u03b54 allele is also associated with a higher risk of Alzheimer-type dementia in MCI patients. [8]", "contents": "Mild Cognitive Impairment -- Pathophysiology. A meta-analysis demonstrated that the cumulative incidence of dementia development was 14.9% for MCI patients older than 65 years who were followed for 2 years. The relative risk for all types of dementia was 3.3 at 2 to 5 years in a cohort of MCI patients and age-matched controls, while the relative risk for the development of Alzheimer Disease was 3.0. People with MCI are at a higher risk of progressing to dementia than age-matched controls. [15] The annual progression rate can be 12% in the general population and up to 20% in high-risk populations. [8] The risk factors for the development of MCI are not consistently associated with progression to dementia. Markers of cerebral dysfunction and those indicating the severity of underlying pathology are more consistently related to the risk of progressing to dementia. [14] More significant functional impairment, neuropsychiatric symptoms at the time of MCI diagnosis, lower neuropsychological test scores, and abnormalities on structural magnetic resonance imaging (hippocampal atrophy) are associated with a greater risk of conversion to dementia. [14] Some studies have noted that advanced age and amnestic MCI were associated with faster progression to dementia. [8] A stepwise multivariate regression analysis study reported that parietal glucose metabolic rate and total Tau proteins could predict progression from MCI to Alzheimer-type dementia. [17] The presence of APOE \u03b54 allele is also associated with a higher risk of Alzheimer-type dementia in MCI patients. [8]"}
{"id": "article-144392_19", "title": "Mild Cognitive Impairment -- Pathophysiology", "content": "Studies have shown that the reversion rate to normal can vary from 14.4% to 55.6%. [15] An average of 20% of individuals with MCI may revert to normal cognition; however, they remain at higher risk of progression back to MCI or dementia than those who were never diagnosed with MCI. [14] [15] Factors associated with reversion to normal include male sex, younger age, single domain MCI, non-amnestic MCI, better scores on objective cognitive instruments (higher Mini-Mental State Examination score or lower CDR sum of boxes score), less functional deficits, lower burden of medical disease, and presence of reversible factors (such as infection). [14]", "contents": "Mild Cognitive Impairment -- Pathophysiology. Studies have shown that the reversion rate to normal can vary from 14.4% to 55.6%. [15] An average of 20% of individuals with MCI may revert to normal cognition; however, they remain at higher risk of progression back to MCI or dementia than those who were never diagnosed with MCI. [14] [15] Factors associated with reversion to normal include male sex, younger age, single domain MCI, non-amnestic MCI, better scores on objective cognitive instruments (higher Mini-Mental State Examination score or lower CDR sum of boxes score), less functional deficits, lower burden of medical disease, and presence of reversible factors (such as infection). [14]"}
{"id": "article-144392_20", "title": "Mild Cognitive Impairment -- Pathophysiology", "content": "MCI does not have a linear trajectory for progression toward dementia or reversion to normal. Patients with stable MCI can change subtypes,\u00a0revert\u00a0to normal, convert to MCI, or progress to dementia. [18] [19]", "contents": "Mild Cognitive Impairment -- Pathophysiology. MCI does not have a linear trajectory for progression toward dementia or reversion to normal. Patients with stable MCI can change subtypes,\u00a0revert\u00a0to normal, convert to MCI, or progress to dementia. [18] [19]"}
{"id": "article-144392_21", "title": "Mild Cognitive Impairment -- Histopathology", "content": "The neuropathology of MCI also displays considerable heterogeneity.", "contents": "Mild Cognitive Impairment -- Histopathology. The neuropathology of MCI also displays considerable heterogeneity."}
{"id": "article-144392_22", "title": "Mild Cognitive Impairment -- Histopathology -- Gross Morphology", "content": "It\u00a0is difficult to distinguish between no cognitive impairment and mild cognitive impairment on autopsy. One study observed a widening of sulci in amnestic MCI and mild AD as compared to no cognitive impairment (NCI) or non-amnestic MCI. [20]", "contents": "Mild Cognitive Impairment -- Histopathology -- Gross Morphology. It\u00a0is difficult to distinguish between no cognitive impairment and mild cognitive impairment on autopsy. One study observed a widening of sulci in amnestic MCI and mild AD as compared to no cognitive impairment (NCI) or non-amnestic MCI. [20]"}
{"id": "article-144392_23", "title": "Mild Cognitive Impairment -- Histopathology -- Amyloid Pathology", "content": "Amyloid beta (A\u03b2) plaques are a characteristic lesion seen in MCI. These plaques appear similar in patients with normal cognition and those with MCI and cannot be used to distinguish between these two states. [20] Plaque density increased with progressing dementia, and the morphology changed from diffuse to neuritic. [20] The Rush Religious Orders Study (RROS) found that although the A\u03b2-amyloid burden in MCI was intermediate between normal controls and early AD, the difference was not statistically significant, suggesting that\u00a0\u03b2 amyloid deposition does not define the pathological transition to MCI. [21]", "contents": "Mild Cognitive Impairment -- Histopathology -- Amyloid Pathology. Amyloid beta (A\u03b2) plaques are a characteristic lesion seen in MCI. These plaques appear similar in patients with normal cognition and those with MCI and cannot be used to distinguish between these two states. [20] Plaque density increased with progressing dementia, and the morphology changed from diffuse to neuritic. [20] The Rush Religious Orders Study (RROS) found that although the A\u03b2-amyloid burden in MCI was intermediate between normal controls and early AD, the difference was not statistically significant, suggesting that\u00a0\u03b2 amyloid deposition does not define the pathological transition to MCI. [21]"}
{"id": "article-144392_24", "title": "Mild Cognitive Impairment -- Histopathology -- Neurofibrillary Tangle (NFT) Pathology", "content": "NFTs are composed of hyperphosphorylated aggregates of the tau protein. NFT deposition is increased in certain anatomical brain regions (such as the Entorhinal cortex and Inferior Parietal Cortex) in MCI patients compared to normal controls, suggesting that NFTs could mark the transition from normal aging to MCI. [20] Studies have also shown that NFTs are present in both amnestic and non-amnestic MCI subtypes, whereas about 52% of MCI cases did not have neuritic plaques. [22] Studies have shown that amnestic MCI is similar to early AD based on NFT distribution. [23] [24]", "contents": "Mild Cognitive Impairment -- Histopathology -- Neurofibrillary Tangle (NFT) Pathology. NFTs are composed of hyperphosphorylated aggregates of the tau protein. NFT deposition is increased in certain anatomical brain regions (such as the Entorhinal cortex and Inferior Parietal Cortex) in MCI patients compared to normal controls, suggesting that NFTs could mark the transition from normal aging to MCI. [20] Studies have also shown that NFTs are present in both amnestic and non-amnestic MCI subtypes, whereas about 52% of MCI cases did not have neuritic plaques. [22] Studies have shown that amnestic MCI is similar to early AD based on NFT distribution. [23] [24]"}
{"id": "article-144392_25", "title": "Mild Cognitive Impairment -- Histopathology -- Neuronal Loss", "content": "Various studies have examined the neuronal changes in MCI, focusing on the medial temporal lobe (MTL), particularly the Entorhinal Cortex (ERC). The RROS study showed\u00a0neuronal reduction in the ERC and ERC atrophy in MCI patients. [20] ERC atrophy was also correlated with impairments in the MMSE, indicating that ERC neurodegeneration influences the progression of MCI. [25] [26]", "contents": "Mild Cognitive Impairment -- Histopathology -- Neuronal Loss. Various studies have examined the neuronal changes in MCI, focusing on the medial temporal lobe (MTL), particularly the Entorhinal Cortex (ERC). The RROS study showed\u00a0neuronal reduction in the ERC and ERC atrophy in MCI patients. [20] ERC atrophy was also correlated with impairments in the MMSE, indicating that ERC neurodegeneration influences the progression of MCI. [25] [26]"}
{"id": "article-144392_26", "title": "Mild Cognitive Impairment -- Histopathology -- Synaptic Degeneration in the Hippocampus", "content": "The hippocampus shows reduced synaptic plasticity in MCI. [20] The number of synapses is reduced in MCI when compared to controls with NCI, and people with early AD have\u00a0a significantly lower number of synapses when compared with MCI and NCI groups. The number of synapses also correlated with MMSE and delayed recall scores. [27]", "contents": "Mild Cognitive Impairment -- Histopathology -- Synaptic Degeneration in the Hippocampus. The hippocampus shows reduced synaptic plasticity in MCI. [20] The number of synapses is reduced in MCI when compared to controls with NCI, and people with early AD have\u00a0a significantly lower number of synapses when compared with MCI and NCI groups. The number of synapses also correlated with MMSE and delayed recall scores. [27]"}
{"id": "article-144392_27", "title": "Mild Cognitive Impairment -- Histopathology -- Cholinergic System and Acetylcholine Receptors", "content": "Reduction in the cholinergic activity in the cortex and loss of neurons in the cholinergic basal forebrain (CBF) has been proposed as a potential mechanism for AD. In MCI, deposition of NFTs was noted in the CBF; however, the number of CBF nucleus basalis (NB) neurons that express choline acetyltransferase enzyme (ChAT) or the acetylcholine transporter was stable. [20] Cholinergic receptor binding in ERC is lower in MCI than in NCI, while it is lower in the hippocampus in AD than in MCI, leading to cognitive deficits. This indicates that cholinergic system dysfunction could be responsible for cognitive changes seen in MCI. [28]", "contents": "Mild Cognitive Impairment -- Histopathology -- Cholinergic System and Acetylcholine Receptors. Reduction in the cholinergic activity in the cortex and loss of neurons in the cholinergic basal forebrain (CBF) has been proposed as a potential mechanism for AD. In MCI, deposition of NFTs was noted in the CBF; however, the number of CBF nucleus basalis (NB) neurons that express choline acetyltransferase enzyme (ChAT) or the acetylcholine transporter was stable. [20] Cholinergic receptor binding in ERC is lower in MCI than in NCI, while it is lower in the hippocampus in AD than in MCI, leading to cognitive deficits. This indicates that cholinergic system dysfunction could be responsible for cognitive changes seen in MCI. [28]"}
{"id": "article-144392_28", "title": "Mild Cognitive Impairment -- Histopathology -- Other Neuropathologies", "content": "Lewy Bodies (LB), cerebral white matter rarefaction (CWMR), infarcts, and cerebral amyloid angiopathy (CAA) are some of the other findings observed in neuropathology studies. Non-amnestic MCI shows a greater distribution of LBs in the temporal lobes than amnestic MCI. [22] CWMR and CAA are equally common in both amnestic and non-amnestic MCI; however, cases with executive dysfunction had a higher frequency of CWMR and CAA. [22] Multiple studies have shown that mixed pathologies are a common feature of MCI.", "contents": "Mild Cognitive Impairment -- Histopathology -- Other Neuropathologies. Lewy Bodies (LB), cerebral white matter rarefaction (CWMR), infarcts, and cerebral amyloid angiopathy (CAA) are some of the other findings observed in neuropathology studies. Non-amnestic MCI shows a greater distribution of LBs in the temporal lobes than amnestic MCI. [22] CWMR and CAA are equally common in both amnestic and non-amnestic MCI; however, cases with executive dysfunction had a higher frequency of CWMR and CAA. [22] Multiple studies have shown that mixed pathologies are a common feature of MCI."}
{"id": "article-144392_29", "title": "Mild Cognitive Impairment -- History and Physical", "content": "Cognitive disorders are diagnosed clinically. Obtaining a comprehensive history from the patient or a reliable informant is important. Sometimes, the patients or their family members or caregivers are concerned about memory loss and may request an evaluation. At other times, neither the patient nor their families report concerns unless the physician asks them directly. Patients with memory loss may have poor insight into their impairment. Hence, it is necessary to obtain collateral information from someone who knows the patient well to obtain an accurate history. Sometimes, the patient's physician or a clinical staff member may be the first to recognize cognitive challenges when a patient misses their appointments, forgets to refill their medications, or\u00a0gets confused by\u00a0simple instructions. Periodically, the initial complaint may be a mood or behavioral problem rather than a cognitive one. Anxiety, depression, apathy, and other personality changes may prompt a request for the assessment.", "contents": "Mild Cognitive Impairment -- History and Physical. Cognitive disorders are diagnosed clinically. Obtaining a comprehensive history from the patient or a reliable informant is important. Sometimes, the patients or their family members or caregivers are concerned about memory loss and may request an evaluation. At other times, neither the patient nor their families report concerns unless the physician asks them directly. Patients with memory loss may have poor insight into their impairment. Hence, it is necessary to obtain collateral information from someone who knows the patient well to obtain an accurate history. Sometimes, the patient's physician or a clinical staff member may be the first to recognize cognitive challenges when a patient misses their appointments, forgets to refill their medications, or\u00a0gets confused by\u00a0simple instructions. Periodically, the initial complaint may be a mood or behavioral problem rather than a cognitive one. Anxiety, depression, apathy, and other personality changes may prompt a request for the assessment."}
{"id": "article-144392_30", "title": "Mild Cognitive Impairment -- History and Physical", "content": "Information about the onset and progression of symptoms should be noted. Usually, the symptoms are gradual in onset and progressive. Sometimes, the patients or their families may attribute these to normal aging. The AAN recommends that all memory concerns be assessed for MCI and not assumed to be due to normal aging. [15]", "contents": "Mild Cognitive Impairment -- History and Physical. Information about the onset and progression of symptoms should be noted. Usually, the symptoms are gradual in onset and progressive. Sometimes, the patients or their families may attribute these to normal aging. The AAN recommends that all memory concerns be assessed for MCI and not assumed to be due to normal aging. [15]"}
{"id": "article-144392_31", "title": "Mild Cognitive Impairment -- History and Physical", "content": "The purpose of the evaluation is to distinguish MCI from normal aging or dementia and to ascertain if any reversible factors may be responsible for the presentation. When determining a patient's baseline function, it is important to gather and consider information about their educational level and occupation. A detailed assessment can identify affected cognitive domains. The complaint should represent a change from the baseline for the patient. The table below shows some examples. [11]", "contents": "Mild Cognitive Impairment -- History and Physical. The purpose of the evaluation is to distinguish MCI from normal aging or dementia and to ascertain if any reversible factors may be responsible for the presentation. When determining a patient's baseline function, it is important to gather and consider information about their educational level and occupation. A detailed assessment can identify affected cognitive domains. The complaint should represent a change from the baseline for the patient. The table below shows some examples. [11]"}
{"id": "article-144392_32", "title": "Mild Cognitive Impairment -- History and Physical", "content": "The cognitive history should be followed by a detailed functional history inquiring about instrumental activities of daily living (IADLs) and basic activities of daily living (BADLs). Changes in complex functions such as difficulty managing finances, medications, or driving should be asked about. In MCI, the patients\u00a0may report functional independence\u00a0alongside their\u00a0cognitive complaints. It can sometimes be challenging to determine if the IADLs are impaired. Patients with higher educational levels or those in cognitively challenging occupations (such as physicians) may report mild changes that affect their professional performance. In contrast, those with lifelong lower-skill jobs may not report any problems. [29] Assessing functional impairment related to cognition is vital to distinguish MCI from dementia. [15]", "contents": "Mild Cognitive Impairment -- History and Physical. The cognitive history should be followed by a detailed functional history inquiring about instrumental activities of daily living (IADLs) and basic activities of daily living (BADLs). Changes in complex functions such as difficulty managing finances, medications, or driving should be asked about. In MCI, the patients\u00a0may report functional independence\u00a0alongside their\u00a0cognitive complaints. It can sometimes be challenging to determine if the IADLs are impaired. Patients with higher educational levels or those in cognitively challenging occupations (such as physicians) may report mild changes that affect their professional performance. In contrast, those with lifelong lower-skill jobs may not report any problems. [29] Assessing functional impairment related to cognition is vital to distinguish MCI from dementia. [15]"}
{"id": "article-144392_33", "title": "Mild Cognitive Impairment -- History and Physical", "content": "A detailed medication review involving prescription and over-the-counter medications is integral to the evaluation.\u00a0The Beers Criteria for Potentially Inappropriate Medication (PIM) Use in Older Adults, developed by the American Geriatrics Society, is useful for identifying medications that can contribute to cognitive impairment. [10]", "contents": "Mild Cognitive Impairment -- History and Physical. A detailed medication review involving prescription and over-the-counter medications is integral to the evaluation.\u00a0The Beers Criteria for Potentially Inappropriate Medication (PIM) Use in Older Adults, developed by the American Geriatrics Society, is useful for identifying medications that can contribute to cognitive impairment. [10]"}
{"id": "article-144392_34", "title": "Mild Cognitive Impairment -- History and Physical", "content": "Neuropsychiatric symptoms\u00a0are quite common in MCI, with 35-85% of patients showing at least one neuropsychiatric symptom. [30] Depression, apathy, anxiety, irritability, sleep problems (difficulty falling asleep, early morning waking, wandering at night), agitation, appetite or eating disorder, and disinhibition can be seen commonly in MCI. Hallucinations and delusions are unusual in MCI patients but associated with worse outcomes if present. [31] It can sometimes be difficult to evaluate if depression and anxiety are a cause of MCI or associated. Screening for sleep-disordered breathing such as OSA, asking questions about vision, hearing, gait, history of falls, recent hospitalizations, tingling/numbness, urinary incontinence, tremors, and speech problems are included in the history.", "contents": "Mild Cognitive Impairment -- History and Physical. Neuropsychiatric symptoms\u00a0are quite common in MCI, with 35-85% of patients showing at least one neuropsychiatric symptom. [30] Depression, apathy, anxiety, irritability, sleep problems (difficulty falling asleep, early morning waking, wandering at night), agitation, appetite or eating disorder, and disinhibition can be seen commonly in MCI. Hallucinations and delusions are unusual in MCI patients but associated with worse outcomes if present. [31] It can sometimes be difficult to evaluate if depression and anxiety are a cause of MCI or associated. Screening for sleep-disordered breathing such as OSA, asking questions about vision, hearing, gait, history of falls, recent hospitalizations, tingling/numbness, urinary incontinence, tremors, and speech problems are included in the history."}
{"id": "article-144392_35", "title": "Mild Cognitive Impairment -- History and Physical", "content": "A complete neurological examination should be performed. This should include assessments for cranial nerves, focal weakness, coordination, ability to stand from a chair without using hand rests, gait, and speech evaluation to look for dysarthria and orthostatic hypotension to identify potential contributors to the cognitive complaint. [9] The history and physical exam help identify conditions such as stroke, NPH, PD, or neuropathy due to vitamin deficiency as a cause of the symptoms.", "contents": "Mild Cognitive Impairment -- History and Physical. A complete neurological examination should be performed. This should include assessments for cranial nerves, focal weakness, coordination, ability to stand from a chair without using hand rests, gait, and speech evaluation to look for dysarthria and orthostatic hypotension to identify potential contributors to the cognitive complaint. [9] The history and physical exam help identify conditions such as stroke, NPH, PD, or neuropathy due to vitamin deficiency as a cause of the symptoms."}
{"id": "article-144392_36", "title": "Mild Cognitive Impairment -- Evaluation", "content": "A standardized cognitive assessment is mandatory to establish a diagnosis of MCI. Standard screening tools that\u00a0are used include the Montreal Cognitive Assessment (MOCA), the Saint Louis University Mental Status Examination (SLUMS), and the Mini-Mental State Exam (MMSE). A history of subjective memory concerns is insufficient to diagnose MCI, and further assessment with a validated tool is required per the AAN practice guidelines. [15]", "contents": "Mild Cognitive Impairment -- Evaluation. A standardized cognitive assessment is mandatory to establish a diagnosis of MCI. Standard screening tools that\u00a0are used include the Montreal Cognitive Assessment (MOCA), the Saint Louis University Mental Status Examination (SLUMS), and the Mini-Mental State Exam (MMSE). A history of subjective memory concerns is insufficient to diagnose MCI, and further assessment with a validated tool is required per the AAN practice guidelines. [15]"}
{"id": "article-144392_37", "title": "Mild Cognitive Impairment -- Evaluation", "content": "The MOCA\u00a0is a 30-point questionnaire specifically designed to detect MCI, takes about 10 minutes to administer, tests multiple cognitive domains, and is validated in multiple languages. The MOCA also accounts for educational level, granting an additional point for patients with less than 12 years of education. [32] Using a cut-off score of 25- 26, MOCA had a sensitivity of 80-100% and specificity of 50-76% for detecting MCI. [9] The MMSE is also a 30-point questionnaire but is less sensitive than the MOCA for detecting MCI, with a sensitivity of 45-60% when using a cut-off score of 27-28. [9] MOCA's assessment tasks are more varied and challenging and can better distinguish patients with mild changes in executive function, complex visuospatial function, and language abilities than the MMSE. [33]", "contents": "Mild Cognitive Impairment -- Evaluation. The MOCA\u00a0is a 30-point questionnaire specifically designed to detect MCI, takes about 10 minutes to administer, tests multiple cognitive domains, and is validated in multiple languages. The MOCA also accounts for educational level, granting an additional point for patients with less than 12 years of education. [32] Using a cut-off score of 25- 26, MOCA had a sensitivity of 80-100% and specificity of 50-76% for detecting MCI. [9] The MMSE is also a 30-point questionnaire but is less sensitive than the MOCA for detecting MCI, with a sensitivity of 45-60% when using a cut-off score of 27-28. [9] MOCA's assessment tasks are more varied and challenging and can better distinguish patients with mild changes in executive function, complex visuospatial function, and language abilities than the MMSE. [33]"}
{"id": "article-144392_38", "title": "Mild Cognitive Impairment -- Evaluation", "content": "Correcting the MMSE score for education can create a ceiling effect for people with low education levels and a floor effect for those with higher educational levels. [34] This means that the MMSE can overestimate the extent of cognitive dysfunction in poorly educated populations and underestimate the highly educated ones. Another limitation of MMSE is that its use is copyrighted. The SLUMS is a 30-point questionnaire with an administration time of 10 minutes. It is more sensitive to detect defects in executive function, commonly impaired in MCI, hence a better screening tool for MCI than the MMSE. The SLUMS has cut-off scores for MCI based on the educational level (unlike the MMSE), is better validated for detecting MCI, and is free to use. [35]", "contents": "Mild Cognitive Impairment -- Evaluation. Correcting the MMSE score for education can create a ceiling effect for people with low education levels and a floor effect for those with higher educational levels. [34] This means that the MMSE can overestimate the extent of cognitive dysfunction in poorly educated populations and underestimate the highly educated ones. Another limitation of MMSE is that its use is copyrighted. The SLUMS is a 30-point questionnaire with an administration time of 10 minutes. It is more sensitive to detect defects in executive function, commonly impaired in MCI, hence a better screening tool for MCI than the MMSE. The SLUMS has cut-off scores for MCI based on the educational level (unlike the MMSE), is better validated for detecting MCI, and is free to use. [35]"}
{"id": "article-144392_39", "title": "Mild Cognitive Impairment -- Evaluation", "content": "The DSM-V or the NIA-AA MCI criteria do not specify the use of a particular screening test; however, the scores need to be 1 to 2 standard deviations below the education and age-adjusted normative means. The scores are used as guidelines and not firm cut-offs for diagnosing MCI. [5] Referral for neuropsychology testing can be considered to specify the type and extent of cognitive deficits, and it\u00a0is instrumental in cases where the deficits are subtle.", "contents": "Mild Cognitive Impairment -- Evaluation. The DSM-V or the NIA-AA MCI criteria do not specify the use of a particular screening test; however, the scores need to be 1 to 2 standard deviations below the education and age-adjusted normative means. The scores are used as guidelines and not firm cut-offs for diagnosing MCI. [5] Referral for neuropsychology testing can be considered to specify the type and extent of cognitive deficits, and it\u00a0is instrumental in cases where the deficits are subtle."}
{"id": "article-144392_40", "title": "Mild Cognitive Impairment -- Evaluation", "content": "Clinicians can also collect information on cognitive function from informants using standardized tools such as the Informant Questionnaire on Cognitive Decline in the Elderly(IQCODE), the Dementia Severity Rating Scale (DSRS), and the AD8. [9] Geriatric Depression Scale can be used to screen for depression, with a score of\u00a0\u22656 suggesting depression. [36] After establishing the diagnosis of MCI based on clinical examination and cognitive testing, diagnostic tests are ordered to determine the etiology of the deficits and identify treatable causes.", "contents": "Mild Cognitive Impairment -- Evaluation. Clinicians can also collect information on cognitive function from informants using standardized tools such as the Informant Questionnaire on Cognitive Decline in the Elderly(IQCODE), the Dementia Severity Rating Scale (DSRS), and the AD8. [9] Geriatric Depression Scale can be used to screen for depression, with a score of\u00a0\u22656 suggesting depression. [36] After establishing the diagnosis of MCI based on clinical examination and cognitive testing, diagnostic tests are ordered to determine the etiology of the deficits and identify treatable causes."}
{"id": "article-144392_41", "title": "Mild Cognitive Impairment -- Evaluation", "content": "Routine laboratory testing includes tests for complete blood counts, thyroid function, vitamin B12, folate, and metabolic panel to check electrolytes, glucose, and renal function to identify reversible causes of MCI. Tests for liver function, syphilis, HIV, hepatitis (B or C), and Lyme disease may be ordered based on clinical suspicion.", "contents": "Mild Cognitive Impairment -- Evaluation. Routine laboratory testing includes tests for complete blood counts, thyroid function, vitamin B12, folate, and metabolic panel to check electrolytes, glucose, and renal function to identify reversible causes of MCI. Tests for liver function, syphilis, HIV, hepatitis (B or C), and Lyme disease may be ordered based on clinical suspicion."}
{"id": "article-144392_42", "title": "Mild Cognitive Impairment -- Evaluation", "content": "The clinical utility of biomarker studies is limited due to a lack of standardized techniques and cut-off scores for diagnosis. The most common biomarkers\u00a0detect pathological changes in AD characterized by low cerebrospinal fluid levels of A\u03b2 42 and elevated levels of the tau protein. [6] These may help identify MCI patients at high risk of progressing to AD, but biomarkers are not recommended as part of the evaluation. [9] [15]", "contents": "Mild Cognitive Impairment -- Evaluation. The clinical utility of biomarker studies is limited due to a lack of standardized techniques and cut-off scores for diagnosis. The most common biomarkers\u00a0detect pathological changes in AD characterized by low cerebrospinal fluid levels of A\u03b2 42 and elevated levels of the tau protein. [6] These may help identify MCI patients at high risk of progressing to AD, but biomarkers are not recommended as part of the evaluation. [9] [15]"}
{"id": "article-144392_43", "title": "Mild Cognitive Impairment -- Evaluation", "content": "Structural neuroimaging studies include magnetic resonance imaging (MRI) or computerized tomography (CT) brain scans. These can help rule out conditions such as stroke, brain tumors, NPH, or subdural hematoma as a cause of cognitive dysfunction. They can also show small vessel ischemic changes or white matter hyperintensities, which\u00a0usually indicate cognitive impairment due to vascular dementia. [6] Volumetric MRI can show hippocampal atrophy correlated with progression to dementia. This imaging modality is\u00a0selectively available at institutions, limiting its clinical use. [6]", "contents": "Mild Cognitive Impairment -- Evaluation. Structural neuroimaging studies include magnetic resonance imaging (MRI) or computerized tomography (CT) brain scans. These can help rule out conditions such as stroke, brain tumors, NPH, or subdural hematoma as a cause of cognitive dysfunction. They can also show small vessel ischemic changes or white matter hyperintensities, which\u00a0usually indicate cognitive impairment due to vascular dementia. [6] Volumetric MRI can show hippocampal atrophy correlated with progression to dementia. This imaging modality is\u00a0selectively available at institutions, limiting its clinical use. [6]"}
{"id": "article-144392_44", "title": "Mild Cognitive Impairment -- Evaluation", "content": "Functional neuroimaging studies such as positron emission tomography (PET) scans with F-fluorodeoxyglucose (FDG) or single photon emission computed tomography (SPECT) evaluate brain function. FDG-PET measures areas of glucose hypometabolism in the brain, indicating neurodegeneration, while SPECT measures cerebral blood flow. [6] These studies are limited to research settings. Genetic testing for the APOE genotype is not recommended as a diagnostic test. [37]", "contents": "Mild Cognitive Impairment -- Evaluation. Functional neuroimaging studies such as positron emission tomography (PET) scans with F-fluorodeoxyglucose (FDG) or single photon emission computed tomography (SPECT) evaluate brain function. FDG-PET measures areas of glucose hypometabolism in the brain, indicating neurodegeneration, while SPECT measures cerebral blood flow. [6] These studies are limited to research settings. Genetic testing for the APOE genotype is not recommended as a diagnostic test. [37]"}
{"id": "article-144392_45", "title": "Mild Cognitive Impairment -- Evaluation", "content": "MCI is a clinical diagnosis, as there are no\u00a0definitive\u00a0screening tests. Periodic clinical assessments are needed to monitor the trajectory of the condition. [15] The AAN guidelines also recommend referral to a cognitive specialist if the clinicians do not have experience treating patients with cognitive impairment. [15]", "contents": "Mild Cognitive Impairment -- Evaluation. MCI is a clinical diagnosis, as there are no\u00a0definitive\u00a0screening tests. Periodic clinical assessments are needed to monitor the trajectory of the condition. [15] The AAN guidelines also recommend referral to a cognitive specialist if the clinicians do not have experience treating patients with cognitive impairment. [15]"}
{"id": "article-144392_46", "title": "Mild Cognitive Impairment -- Treatment / Management", "content": "Treatment of reversible causes should be prioritized; conditions such as OSA, depression, hypothyroidism, vitamin deficiency, and polypharmacy are\u00a0easily treated and may lead to the reversal of cognitive impairment. Vascular risk factors such as hyperlipidemia, hypertension, diabetes mellitus, atrial fibrillation, and tobacco and alcohol use\u00a0should be addressed to slow down ischemic damage.", "contents": "Mild Cognitive Impairment -- Treatment / Management. Treatment of reversible causes should be prioritized; conditions such as OSA, depression, hypothyroidism, vitamin deficiency, and polypharmacy are\u00a0easily treated and may lead to the reversal of cognitive impairment. Vascular risk factors such as hyperlipidemia, hypertension, diabetes mellitus, atrial fibrillation, and tobacco and alcohol use\u00a0should be addressed to slow down ischemic damage."}
{"id": "article-144392_47", "title": "Mild Cognitive Impairment -- Treatment / Management", "content": "Currently, there are no FDA-approved agents for the treatment of MCI. Several pharmacological agents have been studied for efficacy in treating MCI. These include acetylcholine esterase inhibitors donepezil, galantamine, and rivastigmine, homocysteine-lowering B vitamins, flavonoid-containing drinks, vitamin E, vitamin C, transdermal nicotine patch, piribedil, rofecoxib, tesamorelin injections, and V0191. Donepezil and other medications used for AD are not effective in reducing the progression of MCI. [1]", "contents": "Mild Cognitive Impairment -- Treatment / Management. Currently, there are no FDA-approved agents for the treatment of MCI. Several pharmacological agents have been studied for efficacy in treating MCI. These include acetylcholine esterase inhibitors donepezil, galantamine, and rivastigmine, homocysteine-lowering B vitamins, flavonoid-containing drinks, vitamin E, vitamin C, transdermal nicotine patch, piribedil, rofecoxib, tesamorelin injections, and V0191. Donepezil and other medications used for AD are not effective in reducing the progression of MCI. [1]"}
{"id": "article-144392_48", "title": "Mild Cognitive Impairment -- Treatment / Management", "content": "The 2018 AAN practice guidelines advise against pharmacologic or dietary agents for MCI treatment. [15] The guidelines recommend that clinicians discuss with the patient before choosing not to offer cholinesterase inhibitors or prescribing them off-label. Patients should also be provided information about\u00a0relevant clinical trials if they are interested in pharmacologic treatment. [15]", "contents": "Mild Cognitive Impairment -- Treatment / Management. The 2018 AAN practice guidelines advise against pharmacologic or dietary agents for MCI treatment. [15] The guidelines recommend that clinicians discuss with the patient before choosing not to offer cholinesterase inhibitors or prescribing them off-label. Patients should also be provided information about\u00a0relevant clinical trials if they are interested in pharmacologic treatment. [15]"}
{"id": "article-144392_49", "title": "Mild Cognitive Impairment -- Treatment / Management", "content": "Non-pharmacologic interventions such as exercise and cognitive training have also been studied for MCI treatment. A six-month randomized controlled trial resistance training exercise twice weekly showed improved cognitive function compared to weekly balance and tone exercises. [2] Another study showed that multicomponent exercise could improve cognitive function in MCI. A systematic review and meta-analysis have shown the usefulness of cognitive interventions on metacognition and activities of daily living. [1] Cognitively stimulating activities, such as crossword puzzles, card games, and frequent socialization, can help prevent the progression of MCI. [6] The AAN guidelines recommend regular exercise (twice per week) and cognitive interventions as part of management for general health benefits and low risk. [15]", "contents": "Mild Cognitive Impairment -- Treatment / Management. Non-pharmacologic interventions such as exercise and cognitive training have also been studied for MCI treatment. A six-month randomized controlled trial resistance training exercise twice weekly showed improved cognitive function compared to weekly balance and tone exercises. [2] Another study showed that multicomponent exercise could improve cognitive function in MCI. A systematic review and meta-analysis have shown the usefulness of cognitive interventions on metacognition and activities of daily living. [1] Cognitively stimulating activities, such as crossword puzzles, card games, and frequent socialization, can help prevent the progression of MCI. [6] The AAN guidelines recommend regular exercise (twice per week) and cognitive interventions as part of management for general health benefits and low risk. [15]"}
{"id": "article-144392_50", "title": "Mild Cognitive Impairment -- Treatment / Management", "content": "The inherent uncertainty about the progression of MCI and the lack of effective pharmacologic agents necessitates that physicians educate patients about the\u00a0progression to dementia and engage in planning for the future. Patients should be encouraged to designate medical and financial power of attorneys and complete advance directives or living wills if they cannot make such decisions in the future. Potentially hazardous circumstances such as driving, gun safety, and vulnerability to financial scams can be discussed. [6] [15] In addition to discussing long-term planning, the AAN recommends assessing and treating neuropsychiatric symptoms when indicated. [15]", "contents": "Mild Cognitive Impairment -- Treatment / Management. The inherent uncertainty about the progression of MCI and the lack of effective pharmacologic agents necessitates that physicians educate patients about the\u00a0progression to dementia and engage in planning for the future. Patients should be encouraged to designate medical and financial power of attorneys and complete advance directives or living wills if they cannot make such decisions in the future. Potentially hazardous circumstances such as driving, gun safety, and vulnerability to financial scams can be discussed. [6] [15] In addition to discussing long-term planning, the AAN recommends assessing and treating neuropsychiatric symptoms when indicated. [15]"}
{"id": "article-144392_51", "title": "Mild Cognitive Impairment -- Treatment / Management", "content": "Optimizing visual and auditory function is important, as untreated problems can lead to cognitive decline. [38] Targeted interventions to improve gait and balance to reduce the risk of falls should be recommended. [9] Caregivers can experience distress and have conflicting feelings towards the patient in response to the cognitive and behavioral changes seen in MCI. It is important to provide support and services to the caregivers depending on their needs. [7]", "contents": "Mild Cognitive Impairment -- Treatment / Management. Optimizing visual and auditory function is important, as untreated problems can lead to cognitive decline. [38] Targeted interventions to improve gait and balance to reduce the risk of falls should be recommended. [9] Caregivers can experience distress and have conflicting feelings towards the patient in response to the cognitive and behavioral changes seen in MCI. It is important to provide support and services to the caregivers depending on their needs. [7]"}
{"id": "article-144392_52", "title": "Mild Cognitive Impairment -- Differential Diagnosis", "content": "It is important to differentiate MCI from both normal aging\u00a0and dementia. Subjective reports from the patient or a reliable caregiver, a history of functional decline, and objective assessment with a standardized cognitive screening tool help to distinguish these conditions. Reversible causes of MCI, such as depression and OSA, need to be ruled out. MCI can represent the prodromal stage of different types of dementia, and the subtype of MCI can\u00a0provide important clues about the etiology.", "contents": "Mild Cognitive Impairment -- Differential Diagnosis. It is important to differentiate MCI from both normal aging\u00a0and dementia. Subjective reports from the patient or a reliable caregiver, a history of functional decline, and objective assessment with a standardized cognitive screening tool help to distinguish these conditions. Reversible causes of MCI, such as depression and OSA, need to be ruled out. MCI can represent the prodromal stage of different types of dementia, and the subtype of MCI can\u00a0provide important clues about the etiology."}
{"id": "article-144392_53", "title": "Mild Cognitive Impairment -- Differential Diagnosis", "content": "AD can present\u00a0from all\u00a04 MCI subtypes - single or multiple domain A-MCI, single or multiple domain NA-MCI. Depression can present as amnestic MCI. FTD can present as a single domain NA-MCI. Vascular cognitive impairment can present as multiple-domain amnestic or non-amnestic MCI. Lewy body dementia can present as multiple-domain NA-MCI. [2] In Parkinson Disease, a single-domain NA-MCI is usually seen. [1]", "contents": "Mild Cognitive Impairment -- Differential Diagnosis. AD can present\u00a0from all\u00a04 MCI subtypes - single or multiple domain A-MCI, single or multiple domain NA-MCI. Depression can present as amnestic MCI. FTD can present as a single domain NA-MCI. Vascular cognitive impairment can present as multiple-domain amnestic or non-amnestic MCI. Lewy body dementia can present as multiple-domain NA-MCI. [2] In Parkinson Disease, a single-domain NA-MCI is usually seen. [1]"}
{"id": "article-144392_54", "title": "Mild Cognitive Impairment -- Prognosis", "content": "The prognosis of MCI is uncertain. There is great variability in progression rates of MCI to dementia, with studies reporting annual conversion rates from <5%-12-20%. [9] 40-70% of patients with MCI may not progress to dementia for over a decade. [39] About 15-20% of MCI patients will report improved cognition in 1 to 2 years, although this group remains at a higher risk of future cognitive decline. [40]", "contents": "Mild Cognitive Impairment -- Prognosis. The prognosis of MCI is uncertain. There is great variability in progression rates of MCI to dementia, with studies reporting annual conversion rates from <5%-12-20%. [9] 40-70% of patients with MCI may not progress to dementia for over a decade. [39] About 15-20% of MCI patients will report improved cognition in 1 to 2 years, although this group remains at a higher risk of future cognitive decline. [40]"}
{"id": "article-144392_55", "title": "Mild Cognitive Impairment -- Prognosis", "content": "Risk factors associated with MCI progression include amnestic MCI subtype, older age, stroke, diabetes, and lower educational level. [8] APOE genotype may confer a modest risk of progression to AD. [41] Factors associated with reversion to normal cognition include non-amnestic MCI subtype, younger age, higher baseline cognitive function, and higher educational level. [40] MCI subtype classification can be used to estimate progression risk; however, this model has variable predictive accuracy. Current risk prediction models are limited in presaging the risk of progression to dementia. [9] Future risk prediction models need to account for competing risks, such as cardiovascular disease and cancer, that can cause mortality before the patient develops dementia. [9]", "contents": "Mild Cognitive Impairment -- Prognosis. Risk factors associated with MCI progression include amnestic MCI subtype, older age, stroke, diabetes, and lower educational level. [8] APOE genotype may confer a modest risk of progression to AD. [41] Factors associated with reversion to normal cognition include non-amnestic MCI subtype, younger age, higher baseline cognitive function, and higher educational level. [40] MCI subtype classification can be used to estimate progression risk; however, this model has variable predictive accuracy. Current risk prediction models are limited in presaging the risk of progression to dementia. [9] Future risk prediction models need to account for competing risks, such as cardiovascular disease and cancer, that can cause mortality before the patient develops dementia. [9]"}
{"id": "article-144392_56", "title": "Mild Cognitive Impairment -- Complications", "content": "The most important complication of MCI is progression to dementia. Early diagnosis and treatment of MCI are important because they help patients plan for the future so that\u00a0emergencies or late-stage complications\u00a0are avoided. Assessment and treatment of reversible causes can help stabilize or reverse the cognitive changes. [6]", "contents": "Mild Cognitive Impairment -- Complications. The most important complication of MCI is progression to dementia. Early diagnosis and treatment of MCI are important because they help patients plan for the future so that\u00a0emergencies or late-stage complications\u00a0are avoided. Assessment and treatment of reversible causes can help stabilize or reverse the cognitive changes. [6]"}
{"id": "article-144392_57", "title": "Mild Cognitive Impairment -- Deterrence and Patient Education", "content": "Currently, there are no treatments that can reduce the risk of MCI. However, control of vascular risk factors may be important. The treatment of hypertension might reduce the risk of developing MCI and the composite result of MCI and probable dementia. [42] Treating other vascular risk factors, such as diabetes mellitus, hyperlipidemia, and obesity, should follow the cardiovascular and cerebrovascular prevention guidelines. [43] Concurrent treatment is required for conditions such as OSA, depression, hypothyroidism, polypharmacy, and hearing impairment. [43]", "contents": "Mild Cognitive Impairment -- Deterrence and Patient Education. Currently, there are no treatments that can reduce the risk of MCI. However, control of vascular risk factors may be important. The treatment of hypertension might reduce the risk of developing MCI and the composite result of MCI and probable dementia. [42] Treating other vascular risk factors, such as diabetes mellitus, hyperlipidemia, and obesity, should follow the cardiovascular and cerebrovascular prevention guidelines. [43] Concurrent treatment is required for conditions such as OSA, depression, hypothyroidism, polypharmacy, and hearing impairment. [43]"}
{"id": "article-144392_58", "title": "Mild Cognitive Impairment -- Deterrence and Patient Education", "content": "Educating patients and families about the natural course of MCI and the risk factors for progression is important. Clinicians should admit the challenges in predicting individual risk of progression to dementia and emphasize the need for continued monitoring. [9] Patient engagement in advance care planning and outlining goals of care is encouraged depending on the stage of MCI. Providing education regarding the difference between MCI, dementia, and Alzheimer disease\u00a0is helpful to mitigate stress. [43] Patients can be guided to the websites of the\u00a0 Alzheimer's Association (alz.org) and the National Institute on Aging (nia.nih.gov) for more information and resources. [43] Lifestyle interventions should encourage physical activity, a healthy diet, and social or cognitive stimulation. [9] Caregivers of patients with MCI should be encouraged to take care of their own physical and mental well-being to\u00a0reduce caregiver stress. [43]", "contents": "Mild Cognitive Impairment -- Deterrence and Patient Education. Educating patients and families about the natural course of MCI and the risk factors for progression is important. Clinicians should admit the challenges in predicting individual risk of progression to dementia and emphasize the need for continued monitoring. [9] Patient engagement in advance care planning and outlining goals of care is encouraged depending on the stage of MCI. Providing education regarding the difference between MCI, dementia, and Alzheimer disease\u00a0is helpful to mitigate stress. [43] Patients can be guided to the websites of the\u00a0 Alzheimer's Association (alz.org) and the National Institute on Aging (nia.nih.gov) for more information and resources. [43] Lifestyle interventions should encourage physical activity, a healthy diet, and social or cognitive stimulation. [9] Caregivers of patients with MCI should be encouraged to take care of their own physical and mental well-being to\u00a0reduce caregiver stress. [43]"}
{"id": "article-144392_59", "title": "Mild Cognitive Impairment -- Enhancing Healthcare Team Outcomes", "content": "MCI is a heterogenous syndrome with uncertain outcomes. Patients with MCI are at an increased risk of progressing to dementia so early screening and diagnosis are important. MCI can also have reversible causes; collaboration with interprofessional teams is important to improve patient outcomes. Management of memory changes is comprehensive and requires collaboration among various healthcare professionals, community agencies, and the patient and their families. Primary care physicians can refer patients with cognitive complaints to specialists such as geriatricians, neurologists, or psychiatrists if they do not feel confident evaluating such patients or have time constraints. Neuropsychologists can help conduct detailed cognitive assessments to better characterize cognitive deficits. Sleep medicine physicians and advanced practice practitioners can help evaluate and treat sleep disorders. Psychiatric or geriatric psychiatry and other behavioral health team members can manage mood disorders or other behavioral symptoms. Pharmacists can assist primary or specialty care physicians in identifying and avoiding inappropriate medications. Physical and occupational therapists can help with gait training, home safety, and driving safety. Speech-language pathologists can help patients improve communication skills. Social workers help identify community resources and provide education and emotional support to patients and their caregivers. Organizations such as the Local Area Agencies on Aging and the Alzheimer's Association offer caregiver support groups for caregiver training and education. An elder law attorney can help patients appoint medical and financial power of attorney.", "contents": "Mild Cognitive Impairment -- Enhancing Healthcare Team Outcomes. MCI is a heterogenous syndrome with uncertain outcomes. Patients with MCI are at an increased risk of progressing to dementia so early screening and diagnosis are important. MCI can also have reversible causes; collaboration with interprofessional teams is important to improve patient outcomes. Management of memory changes is comprehensive and requires collaboration among various healthcare professionals, community agencies, and the patient and their families. Primary care physicians can refer patients with cognitive complaints to specialists such as geriatricians, neurologists, or psychiatrists if they do not feel confident evaluating such patients or have time constraints. Neuropsychologists can help conduct detailed cognitive assessments to better characterize cognitive deficits. Sleep medicine physicians and advanced practice practitioners can help evaluate and treat sleep disorders. Psychiatric or geriatric psychiatry and other behavioral health team members can manage mood disorders or other behavioral symptoms. Pharmacists can assist primary or specialty care physicians in identifying and avoiding inappropriate medications. Physical and occupational therapists can help with gait training, home safety, and driving safety. Speech-language pathologists can help patients improve communication skills. Social workers help identify community resources and provide education and emotional support to patients and their caregivers. Organizations such as the Local Area Agencies on Aging and the Alzheimer's Association offer caregiver support groups for caregiver training and education. An elder law attorney can help patients appoint medical and financial power of attorney."}
{"id": "article-144392_60", "title": "Mild Cognitive Impairment -- Enhancing Healthcare Team Outcomes", "content": "It is important to recognize racial, ethnic, and cultural perspectives on aging to identify how to connect with patients' support networks and develop a suitable management plan for their needs.", "contents": "Mild Cognitive Impairment -- Enhancing Healthcare Team Outcomes. It is important to recognize racial, ethnic, and cultural perspectives on aging to identify how to connect with patients' support networks and develop a suitable management plan for their needs."}
{"id": "article-144392_61", "title": "Mild Cognitive Impairment -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Mild Cognitive Impairment -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}